High-Throughput Microfluidic 3D Cytotoxicity Assay for Cancer Immunotherapy (CACI-IMPACT Platform)

Adoptive cell transfer against solid tumors faces challenges to overcome tumor microenvironment (TME), which plays as a physical barrier and provides immuno-suppressive conditions. Classical cytotoxicity assays are widely used to measure killing ability of the engineered cytotoxic lymphocytes as therapeutics, but the results cannot represent the performance in clinical application due to the absence of the TME. This paper describes a 3D cytotoxicity assay using an injection molded plastic array culture (CACI-IMPACT) device for 3D cytotoxicity assay to assess killing abilities of cytotoxic lymphocytes in 3D microenvironment through a spatiotemporal analysis of the lymphocytes and cancer cells embedded in 3D extra cellular matrix (ECM). Rail-based microfluidic design was integrated within a single 96-well and the wells were rectangularly arrayed in 2 × 6 to enhance the experimental throughput. The rail-based microstructures facilitate hydrogel patterning with simple pipetting so that hydrogel pre-solution aspirated with 10 μl pipette can be patterned in 10 wells within 30 s. To demonstrate 3D cytotoxicity assay, we patterned HeLa cells encapsulated by collagen gel and observed infiltration, migration and cytotoxic activity of NK-92 cells against HeLa cells in the collagen matrix. We found that 3D ECM significantly reduced migration of cytotoxic lymphocytes and access to cancer cells, resulting in lower cytotoxicity compared with 2D assays. In dense ECM, the physical barrier function of the 3D matrix was enhanced, but the cytotoxic lymphocytes effectively killed cancer cells once they contacted with cancer cells. The results implied ECM significantly influences migration and cytotoxicity of cytotoxic lymphocytes. Hence, the CACI-IMPACT platform, enabling high-throughput 3D co-culture of cytotoxic lymphocyte with cancer cells, has the potential to be used for pre-clinical evaluation of cytotoxic lymphocytes engineered for immunotherapy against solid tumors.

[1]  B. Sacchetti,et al.  CAR-T cells: the long and winding road to solid tumors , 2018, Cell Death & Disease.

[2]  R. Kamm,et al.  Microfluidic assay for simultaneous culture of multiple cell types on surfaces or within hydrogels , 2012, Nature Protocols.

[3]  S. Hopkinson,et al.  Faculty Opinions recommendation of Physical limits of cell migration: control by ECM space and nuclear deformation and tuning by proteolysis and traction force. , 2013 .

[4]  S. Rosenberg,et al.  Adoptive cell transfer as personalized immunotherapy for human cancer , 2015, Science.

[5]  Weiping Zou,et al.  Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy , 2017, Nature Reviews Immunology.

[6]  Pamela A Shaw,et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[7]  D. Fearon,et al.  T cell exclusion, immune privilege, and the tumor microenvironment , 2015, Science.

[8]  Andrea Pavesi,et al.  A 3D microfluidic model for preclinical evaluation of TCR-engineered T cells against solid tumors. , 2017, JCI insight.

[9]  J. Trapani,et al.  Cytotoxic T lymphocyte–induced killing in the absence of granzymes A and B is unique and distinct from both apoptosis and perforin-dependent lysis , 2006, The Journal of cell biology.

[10]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[11]  Robert M. Hoffman,et al.  Physical limits of cell migration: Control by ECM space and nuclear deformation and tuning by proteolysis and traction force , 2013, The Journal of cell biology.

[12]  B. Chapuis,et al.  Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. , 1968, Immunology.

[13]  P. Bousso,et al.  Intravital imaging reveals distinct dynamics for natural killer and CD8(+) T cells during tumor regression. , 2010, Immunity.

[14]  W. Lim,et al.  The Principles of Engineering Immune Cells to Treat Cancer , 2017, Cell.

[15]  スティーブン ジェイ． ブレイクモア，,et al.  How to treat cancer , 2013 .

[16]  Weiyang Jin,et al.  Cytotoxic T Cells Use Mechanical Force to Potentiate Target Cell Killing , 2016, Cell.

[17]  Omkar U. Kawalekar,et al.  CAR T cell immunotherapy for human cancer , 2018, Science.

[18]  Noo Li Jeon,et al.  Microfluidics within a well: an injection-molded plastic array 3D culture platform. , 2018, Lab on a chip.

[19]  Markus Nick,et al.  CheckMATE , 2018, Künstliche Intell..

[20]  D. Beebe,et al.  Evaluating natural killer cell cytotoxicity against solid tumors using a microfluidic model , 2018, Oncoimmunology.

[21]  J. Massagué,et al.  TGF-β Inhibition and Immunotherapy: Checkmate. , 2018, Immunity.

[22]  W. Wilson,et al.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. , 2010, Blood.

[23]  K. Schilbach,et al.  The potential role of γδ T cells after allogeneic HCT for leukemia. , 2018, Blood.

[24]  P. Greenberg,et al.  Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies. , 2017, Cancer cell.

[25]  R. Martin,et al.  CARE-LASS (calcein-release-assay), an improved fluorescence-based test system to measure cytotoxic T lymphocyte activity. , 1994, Journal of immunological methods.

[26]  Pierre Validire,et al.  Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. , 2012, The Journal of clinical investigation.

[27]  V. Weaver,et al.  Tissue Force Programs Cell Fate and Tumor Aggression. , 2017, Cancer discovery.

[28]  D. Speiser,et al.  Regulatory circuits of T cell function in cancer , 2016, Nature Reviews Immunology.

[29]  Hyunjae Lee,et al.  Engineering of functional, perfusable 3D microvascular networks on a chip. , 2013, Lab on a chip.

[30]  Roger D Kamm,et al.  Microfluidic platforms for mechanobiology. , 2013, Lab on a chip.

[31]  Camille Guillerey,et al.  Targeting natural killer cells in cancer immunotherapy , 2016, Nature Immunology.

[32]  Jacco van Rheenen,et al.  Collagen-based cell migration models in vitro and in vivo. , 2009, Seminars in cell & developmental biology.

[33]  Andrea Pavesi,et al.  Microfluidic models for adoptive cell-mediated cancer immunotherapies. , 2016, Drug discovery today.

[34]  Andrea Pavesi,et al.  Characterizing the Role of Monocytes in T Cell Cancer Immunotherapy Using a 3D Microfluidic Model , 2018, Front. Immunol..

[35]  Hong Jiang,et al.  Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy , 2017, Cancer Immunology, Immunotherapy.

[36]  R. Weinberg,et al.  Understanding the tumor immune microenvironment (TIME) for effective therapy , 2018, Nature Medicine.